Logo image of FGEN

FIBROGEN INC (FGEN) Stock Price, Quote, News and Overview

NASDAQ:FGEN - Nasdaq - US31572Q8087 - Common Stock - Currency: USD

0.3215  -0.01 (-2.58%)

After market: 0.323 +0 (+0.47%)

FGEN Quote, Performance and Key Statistics

FIBROGEN INC

NASDAQ:FGEN (5/27/2025, 8:22:19 PM)

After market: 0.323 +0 (+0.47%)

0.3215

-0.01 (-2.58%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High1.53
52 Week Low0.18
Market Cap32.48M
Shares101.04M
Float99.40M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-04 2025-08-04/amc
IPO11-14 2014-11-14


FGEN short term performance overview.The bars show the price performance of FGEN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 -10 -15 -20

FGEN long term performance overview.The bars show the price performance of FGEN in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of FGEN is 0.3215 USD. In the past month the price decreased by -1.23%. In the past year, price decreased by -73.21%.

FIBROGEN INC / FGEN Daily stock chart

FGEN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.08 328.06B
AMGN AMGEN INC 13.46 150.26B
GILD GILEAD SCIENCES INC 14.09 135.70B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.53B
REGN REGENERON PHARMACEUTICALS 13.61 65.13B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 37.83B
ARGX ARGENX SE - ADR 98.77 35.40B
ONC BEIGENE LTD-ADR 6.1 25.76B
BNTX BIONTECH SE-ADR N/A 23.69B
NTRA NATERA INC N/A 21.46B
SMMT SUMMIT THERAPEUTICS INC N/A 19.04B
BIIB BIOGEN INC 8.12 18.81B

About FGEN

Company Profile

FGEN logo image FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 225 full-time employees. The company went IPO on 2014-11-14. The firm is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. The company also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.

Company Info

FIBROGEN INC

350 Bay Street, Suite 100 #6009

San Francisco CALIFORNIA 94158 US

CEO: Enrique Conterno

Employees: 225

FGEN Company Website

FGEN Investor Relations

Phone: 14159781200

FIBROGEN INC / FGEN FAQ

What is the stock price of FIBROGEN INC today?

The current stock price of FGEN is 0.3215 USD. The price decreased by -2.58% in the last trading session.


What is the ticker symbol for FIBROGEN INC stock?

The exchange symbol of FIBROGEN INC is FGEN and it is listed on the Nasdaq exchange.


On which exchange is FGEN stock listed?

FGEN stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for FIBROGEN INC stock?

8 analysts have analysed FGEN and the average price target is 10.2 USD. This implies a price increase of 3072.63% is expected in the next year compared to the current price of 0.3215. Check the FIBROGEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is FIBROGEN INC worth?

FIBROGEN INC (FGEN) has a market capitalization of 32.48M USD. This makes FGEN a Nano Cap stock.


How many employees does FIBROGEN INC have?

FIBROGEN INC (FGEN) currently has 225 employees.


What are the support and resistance levels for FIBROGEN INC (FGEN) stock?

FIBROGEN INC (FGEN) has a resistance level at 0.33. Check the full technical report for a detailed analysis of FGEN support and resistance levels.


Is FIBROGEN INC (FGEN) expected to grow?

The Revenue of FIBROGEN INC (FGEN) is expected to decline by -45.65% in the next year. Check the estimates tab for more information on the FGEN EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy FIBROGEN INC (FGEN) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does FIBROGEN INC (FGEN) stock pay dividends?

FGEN does not pay a dividend.


When does FIBROGEN INC (FGEN) report earnings?

FIBROGEN INC (FGEN) will report earnings on 2025-08-04, after the market close.


What is the Price/Earnings (PE) ratio of FIBROGEN INC (FGEN)?

FIBROGEN INC (FGEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.1).


What is the Short Interest ratio of FIBROGEN INC (FGEN) stock?

The outstanding short interest for FIBROGEN INC (FGEN) is 3.78% of its float. Check the ownership tab for more information on the FGEN short interest.


FGEN Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

FGEN Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to FGEN. Both the profitability and financial health of FGEN have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

FGEN Financial Highlights

Over the last trailing twelve months FGEN reported a non-GAAP Earnings per Share(EPS) of -0.1. The EPS increased by 95.69% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -6.06%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%115.15%
Sales Q2Q%-95.1%
EPS 1Y (TTM)95.69%
Revenue 1Y (TTM)-38.58%

FGEN Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to FGEN. The Buy consensus is the average rating of analysts ratings from 8 analysts.

For the next year, analysts expect an EPS growth of -8.37% and a revenue growth -45.65% for FGEN


Ownership
Inst Owners36.98%
Ins Owners0.63%
Short Float %3.78%
Short Ratio3.49
Analysts
Analysts80
Price Target10.2 (3072.63%)
EPS Next Y-8.37%
Revenue Next Year-45.65%